Inflammatory signaling in pulmonary arterial hypertension: the controversial role of CRP, and the search for new therapies.
Maciocia
Paul M
PM
D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D000959:Antihypertensive Agents / Q000494:pharmacology*; D000069059:Atorvastatin; D002097:C-Reactive Protein / Q000378:metabolism; D018932:Chemokine CCL2 / Q000378:metabolism; D006538:Heptanoic Acids / Q000494:pharmacology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000276:immunology; D018836:Inflammation Mediators / Q000378:metabolism*; D015850:Interleukin-6 / Q000378:metabolism; D009131:Muscle, Smooth, Vascular / Q000187:drug effects* / Q000276:immunology; D016328:NF-kappa B / Q000378:metabolism; D011651:Pulmonary Artery / Q000187:drug effects / Q000276:immunology; D011758:Pyrroles / Q000494:pharmacology*
D000893:Anti-Inflammatory Agents; D000959:Antihypertensive Agents; D018932:Chemokine CCL2; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D018836:Inflammation Mediators; D015850:Interleukin-6; D016328:NF-kappa B; D011758:Pyrroles; D002097:C-Reactive Protein; D000069059:Atorvastatin